Selective Modulation of TNF–TNFRs Signaling: Insights for Multiple Sclerosis Treatment
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Autoimmunity develops when self-tolerance mechanisms are failing to protect healthy tissue. A sustained reaction to self is generated, which includes the generation of effector cells and molecules that destroy tissues. A way to restore this intrinsic tolerance is through immune modulation that aims at refurbishing this immunologically naïve or unresponsive state, thereby decreasing the aberrant immune reaction taking place. One major cytokine has been shown to play a pivotal role in several autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS): Tumor Necrosis Factor alpha (TNFα) modulates the induction and maintenance of an inflammatory process and it comes in two variants, soluble TNF (solTNF) and transmembrane bound TNF (tmTNF). TmTNF signals via TNFR1 and TNFR2, whereas solTNF signals mainly via TNFR1. TNFR1 is widely expressed and promotes mainly inflammation and apoptosis. Conversely, TNFR2 is restricted mainly to immune and endothelial cells and it is known to activate the pro-survival PI3K-Akt/PKB signaling pathway, and to sustain regulatory T cells function. Anti-TNFα therapies are successfully used to treat diseases such as RA, colitis and psoriasis. However, clinical studies with a non-selective inhibitor of TNFα in MS patients had to be halted due to exacerbation of clinical symptoms. One possible explanation for this failure is the non-selectivity of the treatment, which avoids TNFR2 stimulation and its immune and tissue protective properties. Thus, a receptor-selective modulation of TNFα signal pathways provides a novel therapeutic concept that might lead to new insights in MS pathology with major implications for its effective treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes
Micheau, O., & Tschopp, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00521-x · Cited by 2,738 · cited 1×
“TNFR1 has been described as stimulator of effector caspase-mediated apoptosis (35, 36), while TNFR2 promotes cell survival through PI3K-Akt/ PKB signaling pathway (37, 38).”
BackgroundResolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
TNFα promotes proliferation of oligodendrocyte progenitors and remyelination
Arnett, H. A., Mason, J., Marino, M., Suzuki, K., Matsushima, G. K., & Ting, J. P.-Y. (2001) · Nature Neuroscience · doi:10.1038/nn738 · Cited by 1,012 · cited 1×
“In 2001, an important in vivo study investigated the different role of TNFRs in the cuprizone model for demyelination (see Table 1) in mice lacking either TNFα or one its receptors (66).”
BackgroundSchneider, D. S., & Ayres, J. S. (2008) · Nature Reviews Immunology · doi:10.1038/nri2432 · Cited by 783
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628 · cited 2×
“Of importance, mitochondrial dysfunction (5), ROS production (6), misfolding of proteins (7), and release of proapoptotic signals (8) are just few of the consequences (9).”
BackgroundWill the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
TNF receptor 2 pathway: drug target for autoimmune diseases
Faustman, D., & Davis, M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3030 · Cited by 446
Cited by
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target
Mifflin, L., Ofengeim, D., & Yuan, J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0071-y · Cited by 479
Targeting RIPK1 for the treatment of human diseases
Degterev, A., Ofengeim, D., & Yuan, J. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901179116 · Cited by 408
RhoA as a Key Regulator of Innate and Adaptive Immunity
Bros, M., Haas, K., Moll, L., & Grabbe, S. (2019) · Cells · doi:10.3390/cells8070733 · Cited by 193
“The prototypic proinflammatory cytokine tumor necrosis factor-α (TNF-α) which is produced by a large variety of activated immune cells [70] served to enhance the migratory activity of human monocytes as induced by chemokines [71].”
Astrocyte and Oligodendrocyte Cross-Talk in the Central Nervous System
Nutma, E., van Gent, D., Amor, S., & Peferoen, L. A. N. (2020) · Cells · doi:10.3390/cells9030600 · Cited by 183
Zhang, N., Wang, Z., & Zhao, Y. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.03.002 · Cited by 72
Metadata
- Authors
- Pegoretti, V., Baron, W., Laman, J. D., & Eisel, U. L. M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-04-30
- Volume
- 9
- Pages
- 925-925
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2801120436
- Cited by
- 109
- References
- 14
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Modulation of TNF–TNFRs Signaling: Insights for Multiple Sclerosis Treatment. https://app.cochat.ai/papers/10.3389/fimmu.2018.00925
- The paper
- Pegoretti, V., Baron, W., Laman, J. D., & Eisel, U. L. M. (2018). Selective Modulation of TNF–TNFRs Signaling: Insights for Multiple Sclerosis Treatment. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.00925
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.